Last reviewed · How we verify
Cefuroxime (750mg) I.V
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections including lower respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, and meningitis, Perioperative prophylaxis in surgical procedures.
At a glance
| Generic name | Cefuroxime (750mg) I.V |
|---|---|
| Sponsor | Hospital Universitari Vall d'Hebron Research Institute |
| Drug class | Second-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefuroxime works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. It has broad-spectrum activity against both gram-positive and gram-negative bacteria, making it effective against a wide range of infections. The 750mg I.V. formulation provides rapid systemic delivery for serious infections requiring parenteral administration.
Approved indications
- Bacterial infections including lower respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, and meningitis
- Perioperative prophylaxis in surgical procedures
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Phlebitis at injection site
- Hypersensitivity reactions
- Headache
Key clinical trials
- Preoperative Oral Antibiotics With vs Without Mechanical Bowel Preparation to Reduce Surgical Site Infections Following Colonic Resection: an International Randomized Controlled Trial. (PHASE4)
- Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefuroxime (750mg) I.V CI brief — competitive landscape report
- Cefuroxime (750mg) I.V updates RSS · CI watch RSS
- Hospital Universitari Vall d'Hebron Research Institute portfolio CI